アジェンダ
7:15 AM — 7:55 AM
7:55 AM — 8:00 AM
Welcome and Opening Remarks8:00 AM — 8:45 AM
Keynote Session8:45 AM — 10:45 AM
Quality Considerations for Biosimilarity10:45 AM — 11:15 AM
Demonstration of Biosimilarity: Nonclinical Considerations and Challenges11:15 AM — 11:30 AM
11:30 AM — 1:00 PM
Clinical - Part I1:00 PM — 2:00 PM
2:00 PM — 3:30 PM
Clinical - Part II3:30 PM — 4:00 PM
4:00 PM — 5:30 PM
Lessons from the EU5:30 PM — 6:30 PM
7:30 AM — 8:30 AM
8:30 AM — 10:00 AM
Commercialization10:00 AM — 10:30 AM
10:30 AM — 12:00 PM
Postmarketing and Risk Management12:00 PM — 1:00 PM
1:00 PM — 2:30 PM
Global Considerations2:30 PM — 3:00 PM
3:00 PM — 4:00 PM
Monoclonal Antibodies4:00 PM — 4:30 PM
Closing Remarks